Cannabis remains a Schedule I controlled substance under federal law, but the Drug Enforcement Administration has a proposed rule pending that would move marijuana to Schedule III. The DEA has taken public comment and held formal administrative hearings on that proposal, and no final rule has been published. While the rescheduling question plays out, DEA enforcement centers on unlicensed sellers, interstate trafficking, and hemp-derived THC products rather than state-licensed dispensaries.
Cannabis Legal News: DEA Rescheduling Update
Is the DEA rescheduling cannabis right now?
Yes, a rescheduling proposal is open, but it is not finished. The rule must clear administrative hearings, review, and a final order before anything changes in the federal schedules.
dea marijuana schedule change news
- October 2022: The White House directed health and justice officials to review how marijuana is scheduled.
- August 2023: The Department of Health and Human Services recommended placing marijuana in Schedule III.
- May 2024: The DEA published a proposed rule to reschedule marijuana to Schedule III and opened a public comment period that drew tens of thousands of responses.
- Since then: The DEA has run administrative hearings before an administrative law judge, where supporters and opponents present evidence on the medical and abuse-potential findings.
Does rescheduling make cannabis legal?
No. Schedule III is still a controlled substance category, so rescheduling would not legalize cannabis, create a federal retail market, or override state licensing rules. Selling cannabis outside a state-regulated system and possessing it in states without legal programs would remain federal offenses. A Schedule III placement mainly changes tax treatment, research access, and how the drug is regulated rather than who can sell it.
dea cannabis enforcement news 2025
What would Schedule III change in practice?
- Taxes: Section 280E of the tax code blocks deductions for businesses trafficking in Schedule I or II drugs. Moving to Schedule III would let state-licensed operators deduct ordinary business expenses, which could ease margins and prices over time.
- Research: Schedule III carries lower registration barriers, which tends to expand clinical studies and drug-development work.
- Medical recognition: Placement in Schedule III signals accepted medical use, but it does not equal FDA approval of any cannabis product.
- Criminal law: Trafficking penalties, import rules, and the ban on federal interference with state medical programs stay in place.
How is the DEA treating hemp-derived THC like delta-8 and THCA?
Federal law exempts hemp, defined as cannabis with no more than 0.3 percent delta-9 THC on a dry weight basis. The DEA has taken the position that cannabinoids produced by chemical synthesis or conversion, including many delta-8 products, fall outside that hemp exemption and are controlled substances. THCA and other hemp-derived intoxicants sit in a genuine gray zone, and several states have moved to ban them while Congress debates tighter hemp language.
Are delta-8 products sold in stores legal?
It depends on state law and on how the product was made and tested. A delta-8 item that was synthetically converted from CBD can be a controlled substance under federal law even when a store displays it openly.
What is the DEA actually enforcing against?
Federal enforcement priorities target the unregulated side of the market rather than compliant retail. Common targets include:
- Unlicensed storefronts and delivery services operating outside state programs.
- Interstate smuggling and distribution across state lines.
- Illicit cultivation on public land and diversion from licensed supply chains.
- Hemp-derived products that exceed THC limits or result from synthetic conversion.
What does this mean for cannabis shoppers in legal states?
For now, nothing about your purchase changes because of the federal proposal. The practical value of rescheduling, if it is finalized, shows up in lower operating costs for licensed businesses and in more consistent product testing and labeling. Buying from a licensed, lab-tested store remains the safest route, since unregulated hemp-derived products carry no testing requirement and no potency guarantee.
What should you watch next?
- The final rule: A signed DEA order, followed by federal register publication, is the moment rescheduling takes effect.
- Court challenges: Either side in the hearings can sue, which can delay implementation.
- Hemp legislation: Congress continues to debate limits on intoxicating hemp cannabinoids, which would reshape shelves quickly.
- State action: State bans and licensing rules often move faster than federal scheduling.
The short version
Cannabis is federally illegal today, a Schedule III proposal is pending with no final rule, and the DEA is focused on illicit operators and unregulated hemp-derived THC. Expect federal rules to lag well behind the state-legal market you already shop in.